...
首页> 外文期刊>Beilstein journal of organic chemistry. >Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review
【24h】

Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review

机译:熊去氧胆酸(UDCA)合成的最新进展:严格的审查

获取原文
           

摘要

Ursodeoxycholic acid (UDCA) is a pharmaceutical ingredient widely used in clinics. As bile acid it solubilizes cholesterol gallstones and improves the liver function in case of cholestatic diseases. UDCA can be obtained from cholic acid (CA), which is the most abundant and least expensive bile acid available. The now available chemical routes for the obtainment of UDCA yield about 30% of final product. For these syntheses several protection and deprotection steps requiring toxic and dangerous reagents have to be performed, leading to the production of a series of waste products. In many cases the cholic acid itself first needs to be prepared from its taurinated and glycilated derivatives in the bile, thus adding to the complexity and multitude of steps involved of the synthetic process. For these reasons, several studies have been performed towards the development of microbial transformations or chemoenzymatic procedures for the synthesis of UDCA starting from CA or chenodeoxycholic acid (CDCA). This promising approach led several research groups to focus their attention on the development of biotransformations with non-pathogenic, easy-to-manage microorganisms, and their enzymes. In particular, the enzymatic reactions involved are selective hydrolysis, epimerization of the hydroxy functions (by oxidation and subsequent reduction) and the specific hydroxylation and dehydroxylation of suitable positions in the steroid rings. In this minireview, we critically analyze the state of the art of the production of UDCA by several chemical, chemoenzymatic and enzymatic routes reported, highlighting the bottlenecks of each production step. Particular attention is placed on the precursors availability as well as the substrate loading in the process. Potential new routes and recent developments are discussed, in particular on the employment of flow-reactors. The latter technology allows to develop processes with shorter reaction times and lower costs for the chemical and enzymatic reactions involved.
机译:熊去氧胆酸(UDCA)是临床上广泛使用的药物成分。作为胆汁酸,在胆汁淤积性疾病的情况下,它可溶解胆固醇胆结石并改善肝脏功能。 UDCA可以从胆酸(CA)获得,胆酸是最丰富,最便宜的胆汁酸。目前可获得的用于获得UDCA的化学路线可产生约30%的最终产物。对于这些合成,必须执行需要有毒和危险试剂的几个保护和脱保护步骤,从而导致产生一系列废品。在许多情况下,首先需要从胆汁中的牛磺酸和糖基化的衍生物制备胆酸,因此增加了合成方法的步骤的复杂性和复杂性。由于这些原因,已经进行了一些研究,以开发从CA或鹅脱氧胆酸(CDCA)开始的用于合成UDCA的微生物转化或化学酶促方法。这种有前途的方法使几个研究小组将注意力集中在利用非病原性,易于管理的微生物及其酶进行生物转化的研究上。特别地,所涉及的酶促反应是选择性水解,羟基官能的差向异构化(通过氧化和随后的还原)以及类固醇环中合适位置的特异性羟基化和脱羟基。在此小型审查中,我们通过报告的几种化学,化学酶和酶途径对UDCA生产的技术水平进行了批判性分析,突出了每个生产步骤的瓶颈。在此过程中,应特别注意前驱物的可用性以及基材的装载量。讨论了潜在的新路线和最新发展,特别是在使用流动反应器方面。后一种技术可以开发出反应时间更短,涉及的化学和酶促反应成本更低的工艺。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号